Postpartum depression affects about one in seven women after childbirth, causing persistent sadness, anxiety, and difficulty bonding with the baby. Standard treatment combines therapy with antidepressants like sertraline or escitalopram, which take weeks to work. Research now focuses on faster-acting treatments and on understanding the hormonal changes that trigger depression in some women.
What's actually going on in research
Trials are testing zuranolone, a pill designed specifically for postpartum depression that works in days rather than weeks. Researchers are also studying brexanolone infusions for severe cases, psilocybin-assisted therapy, digital mental health tools, and the role of allopregnanolone — a hormone that drops sharply after delivery. Some studies examine whether treating depression during pregnancy prevents postpartum symptoms.
Rapid-acting neurosteroids
Zuranolone was FDA-approved in 2023 for postpartum depression and works within two weeks by restoring GABA activity in the brain. Trials continue to refine dosing and identify who benefits most from this approach.
Prevention trials
Studies are testing whether starting antidepressants in late pregnancy can prevent postpartum depression in high-risk women. Other trials examine whether psychological interventions during pregnancy reduce the likelihood of depression after birth.
Digital interventions
Researchers are testing apps and online therapy programs designed for new mothers, aiming to improve access to treatment. Some studies examine whether these tools work as well as in-person care.
What to know before you search
Eligibility typically depends on symptom severity, timing since delivery, whether you're breastfeeding, and previous mental health history.
What types of trials are currently open
- Treatment trials — Testing medications like zuranolone or new antidepressants to see how quickly they relieve postpartum depression symptoms.
- Prevention trials — Studying whether medications or therapy started during pregnancy can prevent depression after delivery in women at high risk.
- Infusion studies — Testing brexanolone, a neurosteroid given as a continuous infusion over 60 hours for severe postpartum depression.
- Therapy trials — Comparing different types of counseling, including cognitive behavioral therapy and interpersonal therapy, often delivered through telehealth.
- Digital health studies — Testing smartphone apps and online programs that provide therapy, symptom tracking, and support for new mothers.
Recently added Postpartum Depression trials
Take a new medication to reduce postpartum depression symptoms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause
Try a wearable morning light therapy device for postpartum depression
The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.
Find Postpartum Depression trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.